SMS Pharmaceuticals Announces 38th AGM on Sep 29, 2026; Proposes ₹0.40 Dividend
SMS Pharmaceuticals will hold its 38th AGM on September 29, 2026, via VC/OAVM. The company will distribute its FY25-26 Integrated Annual Report. A dividend of ₹0.40 per share is proposed, with a record date of September 22, 2026.
The announcement pertains to standard corporate governance procedures like the AGM and dividend declaration, which are expected events and do not represent a significant deviation or new development for the company.
The announcement is a routine corporate disclosure regarding the AGM and dividend, with no significant positive or negative financial implications presented.
SMS Pharmaceuticals Limited has announced that its 38th Annual General Meeting (AGM) is scheduled to be held on Tuesday, September 29, 2026, at 10:30 AM IST. The meeting will be conducted through Video Conference (VC) / Other Audio-Visual Means (OAVM), in compliance with MCA and SEBI circulars.
The company is dispatching a letter with a web-link and QR code for its Integrated Annual Report for the Financial Year 2025-26 to shareholders whose email addresses are not registered. This report is also available on the company's website, www.smspharma.com, under the 'Investors' > 'Annual Report' > 'Annual Reports 2026' section.
Furthermore, SMS Pharmaceuticals Limited has proposed a dividend of ₹0.40 per equity share of face value ₹1 each. The record date for determining the eligibility of shareholders for this dividend is September 22, 2026. The dividend, if declared, will be paid within 30 days from the date of declaration. Shareholders holding shares in physical form are advised to update their PAN and KYC details by the record date to ensure timely credit of dividends.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.